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Abstract
Background:  Naturally acquired immunity to blood-stage Plasmodium falciparum infection
develops with age and after repeated infections. In order to identify immune surrogates that can
inform vaccine trials conducted in malaria endemic populations and to better understand the basis
of naturally acquired immunity it is important to appreciate the temporal stability of cellular and
humoral immune responses to malaria antigens.
Methods: Blood samples from 16 adults living in a malaria holoendemic region of western Kenya
were obtained at six time points over the course of 9 months. T cell immunity to the 42 kDa C-
terminal fragment of Merozoite Surface Protein-1 (MSP-142) was determined by IFN-γ ELISPOT.
Antibodies to the 42 kDa and 19 kDa C-terminal fragments of MSP-1 were determined by serology
and by functional assays that measure MSP-119 invasion inhibition antibodies (IIA) to the E-TSR
(3D7) allele and growth inhibitory activity (GIA). The haplotype of MSP-119 alleles circulating in the
population was determined by PCR. The kappa test of agreement was used to determine stability
of immunity over the specified time intervals of 3 weeks, 6 weeks, 6 months, and 9 months.
Results: MSP-1 IgG antibodies determined by serology were most consistent over time, followed
by MSP-1 specific T cell IFN-γ responses and GIA. MSP-119 IIA showed the least stability over time.
However, the level of MSP-119 specific IIA correlated with relatively higher rainfall and higher
prevalence of P. falciparum infection with the MSP-119 E-TSR haplotype.
Conclusion: Variation in the stability of cellular and humoral immune responses to P. falciparum
blood stage antigens needs to be considered when interpreting the significance of these
measurements as immune endpoints in residents of malaria endemic regions.
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Background
Individuals living in areas where transmission of Plasmo-
dium falciparum is intense and stable develop naturally
acquired immunity that is characterized by a high degree
of protection against high-density parasitaemia and clini-
cal illness. This immunity develops as a consequence of
experiencing multiple episodes of blood stage infection
throughout infancy and childhood, and may be lost, or
markedly diminished, in the absence of periodic boosting
by clinically asymptomatic blood stage infections during
adulthood [1]. Adaptive cellular and humoral immune
responses to blood stage malaria antigens may be influ-
enced by the intensity and temporal pattern of exposure to
infective mosquitoes, the duration and intensity of parasi-
taemia, the severity of illness, and the degree of immune
system maturity [1,2]. Appreciating the contribution of
these environmental variables and understanding how
they influence discrete immune measurements is compli-
cated by observations that malaria infection can suppress
T cell responses while boosting B cell and antibody
responses, with age as an important confounder [3,4].
Many studies have examined the relationship between
antibody responses to P. falciparum merozoite antigens
and susceptibility to blood stage infection or mild malaria
during childhood. Some, but not all, have reported a sig-
nificant association of IgG antibody levels to the C-termi-
nal region of MSP-1 with parasitological and clinical
phenotypes such as parasitaemia and fever with parasitae-
mia [5-10]. The decay of anti-malarial IgG antibodies has
been examined in Kenyan children who present with
acute mild malaria. The half life of IgG3 and IgG1 anti-
bodies to C-terminal region of MSP-1, Apical Membrane
Antigen 1, and Erythrocyte Binding Antigen 1 is estimated
to be 6.1 to 9.8 days [11]. On the other hand, antibodies
to MSP-142 appear to persist for at least four months in res-
idents of hypoendemic regions of the Peruvian Amazon
[12]. There have been fewer descriptions of how T cell
immunity to blood stage antigens varies over time [13-
16], and whether T cell and antibody responses are con-
cordant in the same individuals. An appreciation of this
aspect of naturally acquired immunity is important to the
identification and interpretation of immune assays that
may be used as primary and secondary endpoints in clin-
ical vaccine trials that assess immunogenicity and protec-
tive efficacy in malaria endemic populations.
The goal of this study was to advance understanding of the
temporal stability of quantifiable immune responses to
the C-terminal region of P. falciparum MSP-1 by adults
who are clinically immune to malaria. Assays that meas-
ure immune responses to the 3D7 and FVO alleles of the
C-terminal fragment of MSP-1, both of which have been
included in recent clinical vaccine trials [17-19], were
employed. In addition, in order to determine whether
time-related changes in anti-MSP-1 antibody levels reflect
changes in functional antibody responses to the broad
repertoire of merzoite antigens that affect parasite growth
in vitro, GIA responses to P. falciparum were quantified.
Methods
Study population
Ethical approval was obtained from the Institutional
Review Board for Human Investigation at University Hos-
pitals Case Medical Center and the Ethical Review Com-
mittee at the Kenya Medical Research Institute. Twenty-
four healthy asymptomatic adult female (n = 7) and male
residents (n = 17) with respective median ages 34 and 44
years (age range 18–79 years) from Kanyawegi sub-loca-
tion, Nyanza Province, Kenya participated in this study. A
total of six blood samples from each individual were col-
lected over a period of nine months. Three venous blood
samples (20 ml) were collected at three-week intervals
from August to October 2004 during a period of relatively
low malaria transmission, and again (three collections at
three-week intervals) from April to May 2005 during a
period of high malaria transmission. Data collected at
each time point included the reported history of recent
febrile illness, demographic information (age, gender and
family household members) and the level of asexual par-
asitaemia by blood smear. Data from the 16 participants
who provided blood samples at all 6 time points are
included in the analysis. All of these individuals remained
asymptomatic and reported taking no malaria medication
during the nine-month period observation.
Blood smear examination
Thick and thin blood smears were prepared, fixed in
100% methanol, stained with 5% Giemsa solution, and
examined by light microscopy for P. falciparum-infected
erythrocytes. The density of parasitaemia was expressed as
the number of asexual P. falciparum per μl blood assuming
a leukocyte count of 8,000 per μl.
IFN-γ ELISPOT
IFN-γ ELISPOT was performed as described previously
[13,16,20]. Briefly, peripheral blood mononuclear cells
(PBMCs) were separated from heparin anti-coagulated
blood by Ficoll-Hypaque gradient centrifugation and
incubated for 3.5 days with culture medium alone, 5 μg/
ml 3D7 MSP-142 or FVO MSP-142 (provided by Carole
Long, Malaria Vaccine Development Unit, NIAID, NIH,
Rockville, MD) or 1 μg/ml PHA in microtiter plates coated
with 5 μg/ml of primary anti-IFN-γ antibody (Endogen M-
700A, Worcester, MA). IFN-γ secreting cells were detected
after removal of PBMCs and addition of 0.75 μg/ml of
biotinylated secondary anti-IFN-γ antibody (Endogen M-
700B) followed by horseradish-peroxidase conjugated
strepavidin peroxidase (DAKO PO397) and 1% 3-amino-
9-ethyl-carbazole substrate in -0.1 mol/L acetate buffer.Malaria Journal 2009, 8:162 http://www.malariajournal.com/content/8/1/162
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Spot Forming units (SFU) were counted by Immunospot
Satellite analyzer (Cellular Technology, Cleveland OH).
An IFN-γ ELISPOT assay was considered positive if the fre-
quency of SFU for PBMCs incubated with MSP-142 or PHA
was significantly greater (p < 0.05) than culture medium
alone using a chi-square Fisher's exact test. Only PBMC
samples with strong positive IFN-γ responses to PHA were
included in the analysis (n = 88).
IgG antibody measurements
IgG antibodies to recombinant 3D7 (E-TSR) and FVO (Q-
KNG) alleles of P. falciparum MSP-142 were quantified
serologically by ELISA as described previously [21].
Briefly, Immunolon 4 plates were coated with 0.1 μg per
ml of the 3D7 or FVO allele of MSP-142. Plasma from nine
North American adults never exposed to malaria was used
as a negative control. Plasma from four known malaria
immune Kenyan adults was pooled to create a positive
standard. A standard curve was performed for each plate
tested. The value obtained with a 1:50 dilution of the pos-
itive pool was designated as 100 arbitrary units (AU),
1:100 dilution as 50 AU, 1:200 dilution as 25 AU, 1:500
dilution as 10 AU, 1:1,000 dilution 5 AU, and 1:2,000
dilution as 1 AU. A four-parameter standard fit curve was
constructed from the positive control plasma pool and
applied to sample values. Positive values were greater than
the mean + 3 SD of the value of the individual negative
control plasma samples.
Methods to quantify MSP-119-specific IIA were as
described previously [20,22]. Briefly, D10-PfM3' which
encodes the MSP-119MAD20/3D7/E-TSR allele and an
isogenic D10-PcMEGF parasite line in which the antigen-
ically unrelated P. chabaudi ortholog replaces P. falciparum
MSP-119 were tested in parallel. Ring-stage parasites were
synchronized twice by sorbitol lysis and allowed to
mature to late trophozoite/schizont stages. Purified para-
sites were adjusted to 4% haematocrit with 0.5% infected
red cells, and 50 μl aliquots were placed in 96-well flat-
bottom microtiter plates with an equal volume of 1:5 pre-
diluted plasma in culture medium (final plasma dilution
1:10, final volume 100 μl). The same batch of pre-diluted
plasma was added to the two parasite lines in the same
assay. The cultures were incubated for 26 hours to allow
for schizont rupture and merozoite invasion. 25 μl of re-
suspended cultures were removed, fixed with 0.25% glu-
teraldehyde in PBS for 45 min, and placed in 1 μg Hoechst
33342 (HO) stain (Molecular Probes, Eugene, Oregon) in
400 μl 1× PBS for >24 hours at 4°C [23,24]. Stained cells
were examined using the UV laser on a BD LSR II flow
cytometer to collect data from a minimum of 5 × 104 cells
using Becton-Dickinson FACS Diva 5.01. Ring parasitae-
mia was calculated by quantifying singly infected erythro-
cytes plus multiply infected erythrocytes (quantified as
having two rings) according to flow cytometry gating pre-
viously described [24]. FlowJo 8.5.1 was used to analyse
cytometry data. The mean number of ring-stage parasitae-
mia for duplicate wells was calculated, and results
expressed as a percentage of the ring-stage parasitaemia of
non-immune control plasma (derived from non-malaria
exposed adults) in parallel cultures. The percent change of
invasion inhibition attributable to anti-MSP-119 antibod-
ies was calculated by subtracting the percent invasion of
D10-PfM3' relative to non-immune controls from the per-
cent invasion of D10-PcMEGF relative to non-immune
controls. A positive response was defined as ≥ 5% inhibi-
tion attributable to MSP-119 IIA. Overall antibody-medi-
ated GIA was determined from results of the MSP-119 IIA
assay using growth of the D10-PfM3' line only. Growth
inhibition based on duplicate wells was calculated with
the following equation: 100 – (test plasma parasitaemia/
non-immune plasma parasitaemia) × 100. Plasma from
four malaria naïve US adults was pooled as the non-
immune plasma controls. A positive response was defined
as ≥ 15% D10 inhibition.
MSP-119 haplotype determination
DNA was extracted from 200 μl venous blood using
QIAamp DNA blood mini kit (Qiagen Corp, Valencia,
CA). Methods to quantify the four major MSP-119 haplo-
types by PCR/ligase detection reaction fluorescent micro-
sphere assay (PCR/LDR-FMA) were as described
previously [25].
Rainfall data
Monthly rainfall data for the Kisumu area was purchased
from the Kenyan Ministry of Transport, Kenya Meteoro-
logical Department. Rainfall from July 2004 to July 2005
was recorded as mm per month.
Statistical analysis
Kappa analyses were conducted using SAS Version 8.2
(Carey, NC).
Quantitative differences between experimental groups
were evaluated by paired t test. Pearson's correlation was
used to compare MSP-119-specific IIA results with serolog-
ically determined anti-MSP-142  IgG antibody and
responses measured at each time point within each assay.
Generalized Estimating Equation (GEE) was utilized to
examine repeated immune correlates of protection
dichotomous values over time from the same individual.
Mixed linear model was utilized to examine repeated
immune correlates of protection continuous values over
time from the same individual.
Results
Dichotomous immune outcomes and temporal stability
Ninety-six determinations (16 individuals examined at six
time points) were made for each of the four tests. The per-Malaria Journal 2009, 8:162 http://www.malariajournal.com/content/8/1/162
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cent positive outcomes for each test were 70% for MSP-142
IgG ELISA (3D7 and FVO alleles considered together),
46% for overall GIA, 41% for MSP-119-specific IIA, 67%
for T cell 3D7 MSP-142 specific IFN-γ production, and 10%
for T cell FVO MSP-142 specific IFN-γ production. T cell
responses to FVO MSP-142 were disproportionately low in
this population and not evaluated further. Thirty-three
percent of the positive immune outcomes were observed
coincidental with a P. falciparum-positive blood smear.
The kappa test of agreement between paired samples was
used to determine the stability of immune measurements
over four time intervals: three weeks, six weeks, six
months, and nine months. Immune assay results were
expressed as positive or negative using criteria described
in the methods section. Kappa test establishes the percent
agreement of responses beyond chance such that consist-
ent positive responses and/or consistent negative
responses generate higher kappa scores. A kappa score of
0.81–1.00 was regarded as "almost perfect" and consid-
ered to reflect consistent positive or negative results
between paired samples over a specified time interval. A
score of 0.61–0.80 was regarded as "substantial agree-
ment." A score of 0.41–0.60 was regarded as "moderate
agreement," a score of 0.21–0.4 as "fair agreement", and a
score <0.20 as "slight agreement [26,27]." Figure 1 illus-
trates the kappa values for each time interval assessed.
Each time interval was assessed independently. Kappa
scores for 3D7 MSP-142 stimulated IFN-γ production indi-
cate fair to moderate temporal stability over the time
intervals examined. In contrast, kappa scores for serologi-
cally determined IgG antibody to FVO MSP-142 indicate
essentially substantial stability for all time intervals tested.
IgG antibody to 3D7 MSP-142 shows good stability over
three- and six-week intervals, which decreased over the
six-month interval. GIA appears to be moderately stable
over time intervals as long as six months. 3D7 MSP-119-
specific IIA demonstrates fair stability at three-week inter-
vals that disappears at longer time intervals. In summary,
IgG antibody to 3D7 and FVO MSP-142 measured serolog-
ically by ELISA were the most stable over time, followed
by 3D7 MSP-142 IFN-γ responses and GIA. MSP-119 IIA
was the least stable over time with essentially no consist-
ent response lasting more than three weeks.
The GEE final model included categorical data for blood
smear positivity, sex, IFN-γ response, GIA, MSP-119 IIA
and time intervals, allowing for estimation of stability of
repeated observations for each individual. Only MSP-119
IIA showed a significant change from August–October
2004 versus April–May 2005, as illustrated in Figure 2B.
No significant differences in MSP-142 IgG antibody deter-
mined by serology or T cell IFN-γ responses were seen in
these individuals over time using the GEE model.
Quantitative comparisons
Repeated continuous outcomes from each assay were ana-
lyzed with repeated measures models using the PROC
MIXED procedure. Time was included as a linear variable.
3D7 MSP-142 IFN-γ, 3D7 and FVO MSP-142 IgG, and GIA
responses did not change markedly with time, substanti-
ating results found with GEE analysis. MSP-119 IIA was
associated with time increasing 0.1548 units per week (p
= 0.003). Results were not affected by sex or age. Little
fluctuation over time of 3D7 or FVO MSP-142 IgG anti-
body was observed (paired t tests, Figure 2A). Similarly
GIA levels showed little temporal change (paired t test).
However, MSP-119-specific IIA levels increased signifi-
cantly (p = 0.02, paired t test) in the six-month interval
between October 2004 and April 2005 (Figure 2B).
No correlation was observed between 3D7 MSP-119 IIA
and 3D7 or FVO MSP-142 IgG antibody determined by
serology (Pearson's correlation, R2 = 0.052 and 0.0247 for
3D7 and FVO, respectively). Transgenic P. falciparum in
which FVO MSP-119 has been replaced by the P. chabaudi
ortholog have not been constructed. Additionally, there
was no correlation between GIA and MSP-142 IgG (R2 =
0.0235 and 0.0036 for 3D7 and FVO, respectively). A
modest positive correlation was observed between the
functional MSP-119 IIA and GIA results (R2 = 0.1512). This
is not surprising since MSP-119 IIA is a component of the
overall anti-malarial antibody activity measured by GIA.
Additional materials (Additional Files 1, 2, 3, 4 and 5)
demonstrate for each immunologic assay correlation
matrices between all the time points and spaghetti plots
illustrating the quantitative data over time. While the
kappa test takes into account agreement between positive
responses and negative responses, correlations are driven
only by the magnitude of the positive response. Thus,
kappa and correlation tests measure different outcomes.
3D7 MSP-142 IFN-γ correlations ranged from R2 0.001 –
0.81 depending on the time interval examined. 3D7 and
FVO MSP-142 IgG correlations ranged from R2 0.001–0.81
and 0.77 – 0.95, respectively. MSP-119 IIA and GIA corre-
lations ranged from R2 0.001–0.55 and 0.2 – 0.69, respec-
tively, depending on the time intervals examined.
Association of rainfall with blood stage infection, MSP-119 
haplotypes, and MSP-119 IIA
Rainfall was used to estimate transmission intensity since
this climatic variable has previously been found to track
with  P. falciparum transmission in this area of Kenya
[28,29]. Cumulative rainfall from August from September
2004 was 336 mm, which was lower than from April to
May 2005 when it was 471 mm (Figure 3). Twelve of 48
blood samples obtained during the former period were
positive for P. falciparum by microscopy compared with
27 of 48 samples during the latter period (p = 0.0018, chi-Malaria Journal 2009, 8:162 http://www.malariajournal.com/content/8/1/162
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Temporal stability of five immunologic assays at various time intervals Figure 1
Temporal stability of five immunologic assays at various time intervals. X axis: The first group of columns repre-
sents assays performed at four different 3-week intervals (Aug. 24 to Sept. 15, Sept. 15 to Oct 6, Apr. 6 to May 5, May 5 to 
May24). The second group of columns represents assays performed at two different 6-week intervals (Aug. 24 to Oct. 6, Apr. 
6 to May 24). The single columns at far right represent assays performed at a single 6-month (Oct. 6 to Apr. 6) and 9-month 
interval (Aug. 24 to May 24). Horizontal dotted lines across 3-week or 6-week columns indicate average kappa scores. Sample 
number comparison represented by each column is 16 unless otherwise specified. Y axis: Kappa score: Scores of 0.81–1.0, 
0.61–0.80, 0.41–0.60, 0.21–40, and <0.20 indicate, respectively, almost perfect agreement and high stability, substantial stability, 
moderate stability, fair stability, and slight to no stability. A: 3D7 MSP-142 stimulated INF-γ production measured by ELISPOT. 
Kappa scores indicate moderate temporal stability over 3-week intervals (0.41) with fair stability (0.22) at 6-week intervals. 
Sample number for each column from left to right is 15, 10, 11, 12, 14, 16, and 16. B: 3D7 MSP-142 IgG measured by ELISA. 
Kappa scores indicate high (0.86) and substantial temporal stability (0.72) over 3-week and 6-week intervals. At 6-month and 9-
month intervals, stability was fair and moderate. C: FVO MSP-142 IgG measured by ELISA. Kappa scores indicate high to sub-
stantial temporal stability for all time intervals tested. The average kappa score for 3-week and 6-week intervals is 0.91 and 
0.82. D: MSP-119 IIA. Kappa score at 3-week interval (0.31) indicates fair temporal stability that disappears at longer time inter-
vals. E. Growth Inhibitory Assay (GIA). Kappa scores at 3-week (0.37), 6-week (0.51), and 6-month interval indicate fair to 
moderate stability. The kappa score at the 9-month interval (0.20) indicated the lowest degree of temporal stability.
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square test). The average parasite density during both time
intervals was <100 asexual parasites/μl blood. None of the
participants experienced fever or other symptoms of
malaria at any time during the 9-month observation
period.
The 19 kDa C-terminal fragment of P. falciparum MSP-1
has four predominant alleles based on point mutations
resulting in four non-synonymous amino acid changes: E-
TSR (3D7/PNG-MAD20 type), E-KNG (Uganda-PA type),
Q-KNG (FVO/Wellcome type), and Q-TSR (Indo type).
From August to October 2004, 41 of 48 samples were
tested for MSP-119 haplotypes. By the MSP-119 PCR/LDR-
FMA method, six positive samples had five E-KNG haplo-
types and two Q-KNG haplotypes (one sample had both
the E-KNG and Q-KNG haplotypes). From April to May
2005, 48 samples were tested. Nine positive samples were
detected by MSP-119 PCR/LDR-FMA including three E-
TSR, three E-KNG, and three Q-KNG haplotypes. All of
those with the E-TSR (3D7) haplotype were found
between April and May 2005 which coincided with
increased MSP-119 IIA levels (E-TSR/3D7). In contrast, IgG
antibody to the E-TSR/3D7 haplotype measured by serol-
ogy did not increase.
Association between T cell IFN-γ and humoral immune 
responses
There was no correlation between T cell IFN-γ responses
and antibody responses as determined by correlation
coefficients, kappa test, and GEE at individual time points
or over time.
Discussion
MSP-1 is among the most abundant merozoite surface
proteins of Plasmodium species. It is anchored to the outer
membrane of the merozoite by glycophosphatidylinosi-
tol, and is considered to be essential to the cyclical process
of erythrocyte invasion by malaria parasites. The msp-1
gene is conserved in the genomes of all Plasmodium spe-
cies described to date, and the inability to delete the gene
is consistent with the notion that the protein has an essen-
tial and non-redundant role in blood stage infection [30].
Studies of malaria naïve primates vaccinated with the
penultimate and ultimate C-terminal 42 kDa and 19 kDa
processed fragments of P. falciparum MSP-1 have shown
Temporal stability of quantitative measurements of antibod- ies Figure 2
Temporal stability of quantitative measurements of 
antibodies. A: MSP-142 IgG levels (Mean ± SEM) measured 
by ELISA (solid circles, FVO; solid triangles, 3D7) at the 6 
time points. Each time point is separated by approximately 3 
weeks with the exception of October 6 to April 6 time 
points which are separated by 6 months (denoted by two 
short parallel lines through the x-axis). No significant change 
in IgG levels was observed over time. B: GIA (open squares) 
and MSP-119 IIA (open triangles) (Mean ± SEM) at the 6 time 
points. Between October 6 and April 6 time points, a statisti-
cally significant increase in MSP-119 IIA (p = .02, paired t test) 
was observed. No significant change in GIA levels was 
observed over of any of the other time points.
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that induction of immunity to this single merozoite lig-
and can mediate protection against blood stage infection
manifest as reduced or absent parasitaemia and reduced
severity of anaemia [5,6,8,10]. Experimental subunit vac-
cines containing recombinant C-terminal fragments of
MSP-1 have advanced beyond examination of safety and
immunogenicity in malaria naïve humans to studies of
immunogenicity and efficacy in malaria endemic popula-
tions [19,31-33]. The goal of this study was to characterize
the temporal stability of selected immune markers to
MSP-1 in Kenya adults with naturally acquired immunity
to malaria in order to increase knowledge of whether the
temporally unstable and transient nature of antibody
responses to MSP-1 (and more generally other blood stage
antigens) observed in children extends to adults.
Four immune assays were chosen for study based on pre-
vious observations suggesting that they may correlate with
protection against parasitaemia and/or clinical morbidity:
malaria antigen specific T cell IFN-γ measured by ELISPOT
[13,34-37], IgG antibodies to recombinant MSP-142 pro-
teins measured by ELISA [5,6,8,10], MSP-119-specific IIA
[20], and GIA [23,38]. Based on serial observations of 16
adult residents of western Kenya examined over a nine-
month period, these results show that 1) IFN-γ responses
to 3D7 MSP-142 are fair to moderately stable; 2) IgG anti-
bodies to the FVO and 3D7 alleles of MSP-142 measured
serologically by ELISA are most stable over time; and 3)
functional measures of MSP-119 specific IIA is a transient
but potentially sensitive indicator of antibody-mediated
immunity that may reflect recent exposure to P. falciparum
with the corresponding MSP-119 haplotype.
Previous observations indicate that residents of high
transmission regions have attenuated cellular responses to
P. falciparum blood stage antigens in comparison to those
living in low transmission regions or who experience few
malaria episodes [39,40]. The finding that IFN-γ
responses to 3D7 MSP-142 were fair to moderately stable
over the time intervals assessed is consistent with this
observation. Similarly, in a repeat cross-sectional study of
adults and children in western Kenya, IFN-γ T cell
responses to LSA and TRAP peptides in adults were not
stable over a nine-month time interval [16]. The lack of
correlation between humoral and cellular responses to
MSP-1 seen here is consistent with previous studies [10].
The parasitological variables and immune mechanisms
accounting for the instability of MSP-1 specific T cell
cytokine responses are not known. It is possible that
malaria infection per se may alter T cell responses since
blood stage infection has been associated with reduced
IFN-γ responses [41]. In the study described here 41%
(32/96) of PBMC donor samples were positive for asexual
P. falciparum by blood smear, although infection status
had no correlation with IFN-γ ELISPOT results when ana-
lysed by GEE. In addition to extending the current study
design to children and infants, a larger sample size may be
needed to detect small but significant associations. Future
studies that include flow cytometry to measure produc-
tion of other cytokines in addition to IFN-γ, multifunc-
tional T cells, and T cell memory subsets will be needed to
define more clearly the contribution of merozoite anti-
gen-specific T cells in mediating naturally acquired and
vaccine-elicited immunity.
The kappa test is an objective evaluation of agreement of
an experimentally determined immune variable over
defined time intervals. An inherent bias in interpreting the
data described here (or any analysis of this type) is the cri-
teria used to determine a positive or negative immune
response. Widely accepted criteria to differentiate positive
and negative responses for ELISPOT and ELISA assays
were used in this study. Functional antibody assays (GIA
and MSP-119-specific IIA) can have arbitrary cut-off values
to define a positive or negative response. Vaccine studies
have often used a GIA cut-off of 15% for positive respond-
ers, as the case in this study. On the other hand, cut-off
thresholds for MSP-119-specific IIA have not been well
defined. In a previous analysis, high levels (upper quar-
tile) of MSP-119 IIA were associated with protection in
Kenyan adults living in a highland area where malaria
transmission is low and unstable [20]. In contrast, MSP-
119 IIA levels are frequently low or absent in Kenyans liv-
ing in the nearby holoendemic area where the current
study was performed (manuscript in preparation).
The lack of correlation between IgG antibodies measured
by ELISA and functional antibody assays is not surprising.
It is becoming more apparent that functional and sero-
logic assays of antibody responses to merozoite proteins
measure different aspects of antibody-mediated immu-
nity in naturally exposed populations [20,38,42]. A strong
correlation between ELISA and functional antibody assays
is observed in vaccination studies that involve malaria
naïve humans [18,43]. In contrast, vaccine studies con-
ducted in malaria endemic regions have not found con-
sistent correlations between ELISA and functional assay
responses [44]. Of note with respect to the current obser-
vations, GIA and MSP-119 IIA assays had fewer positive
responses than did serologically measured responses. This
may have resulted in greater temporal stability of results
by ELISA but would not have affected quantitative com-
parisons. Stable ELISA measured antibody responses to
MSP-1 have been previously observed in naturally
immune adults [32].
The results of this study showing an increased level of
MSP-119-specific IIA during periods of increased rainfall
and blood stage parasitaemia suggest that this assay may
be a transient but nevertheless potentially sensitive indica-
tor of immunity that reflects recent experience with blood
stage parasitaemia. Moreover, the finding of an increase inMalaria Journal 2009, 8:162 http://www.malariajournal.com/content/8/1/162
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MSP-119-specific IIA suggests that functional as opposed
to serologic measurements of antibodies may be impor-
tant in studying polymorphic vaccine candidate antigens.
In this regard, more extensive studies examining func-
tional antibody assays that detect not only erythrocyte
invasion by P. falciparum bearing MSP-119 FVO (Q-KNG)
allele but also other polymorphic merozoite proteins is
warranted.
Conclusion
These data underscore the lack of temporal stability of cur-
rent assays that measure humoral and cellular immune
responses to MSP-1 in adults with naturally acquired
immunity to P. falciparum. Functional antibody measure-
ments of MSP-119-specific IIA may be a transient indicator
of recent haplotype-specific infection. Overcoming the
temporal instability of immune responses generated
against MSP-1 beyond those demonstrated by clinically
immune adults may be necessary to develop a protective
blood stage vaccine.
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